The Insulin Resistance Engine: Why PMOS Is a Metabolic Condition First

This is the explainer both of our other PMOS articles point back to. If you only read one thing about the condition, read this.

What insulin resistance actually is

Insulin is the hormone that lets your cells take up glucose from the blood and use it for energy. In insulin resistance, your cells respond poorly to insulin's signal. Your body's fix is to shout louder: the pancreas pumps out more insulin to force the same job to get done. The result is chronically elevated insulin in the blood, a state called hyperinsulinemia.

For a while, this compensation works and blood sugar stays normal. That is exactly why insulin resistance is so easy to miss. A standard fasting glucose test can look fine for years while insulin levels are quietly climbing in the background. The problem is not the glucose yet. It is the insulin.

Insulin resistance is recognized as a major driver of PMOS, and it does not behave the same way in every tissue or every woman. It varies across muscle, liver, and fat, and it varies by PMOS subtype. Genetics, inflammation, and excess body fat all worsen it, which is part of why the condition looks so different from one woman to the next.

The loop that ties it all together

Here is where hyperinsulinemia stops being an abstract lab value and starts producing symptoms.

Excess insulin tells the ovaries to make more androgens. Insulin acts on the theca cells of the ovary and amplifies the signal from luteinizing hormone, pushing the ovary to produce more testosterone and related androgens. This is the direct line between a metabolic problem and a reproductive one.

Excess insulin lowers SHBG. The liver makes a protein called sex hormone binding globulin (SHBG) that binds testosterone and keeps it inactive in the bloodstream. High insulin suppresses SHBG. Less SHBG means more free, active testosterone circulating, even if total testosterone looks only mildly elevated. This is why the free androgen index, not just total testosterone, tells the real story.

Free androgens produce the visible symptoms. The elevated free testosterone drives the classic features: irregular or absent ovulation, acne, and unwanted hair growth. The ovulatory dysfunction is what links the condition to irregular cycles and to infertility.

Fat closes the loop. Insulin resistance promotes fat storage, especially visceral fat around the organs. Visceral fat is metabolically active and inflammatory, and it worsens insulin resistance further. So the loop feeds itself: insulin resistance to hyperinsulinemia to androgens and fat storage to more insulin resistance. PMOS also shares a low-grade inflammatory state with obesity, type 2 diabetes, and cardiovascular disease, which is part of what makes it a whole-body condition rather than a localized one.

Why this is not simply an obesity problem

It would be easy to read all of this as "PMOS is caused by being overweight." That is too simple, and getting it wrong matters.

Insulin resistance shows up in lean women with PMOS too. A woman can have a normal BMI and still have significant, tissue-level insulin resistance driving her androgens and her cycles. This is the "lean PMOS" phenotype, and it is routinely missed precisely because clinicians look at weight instead of measuring insulin directly. Excess weight amplifies the engine, but it is not the whole engine. Some women are running the loop at a lower body weight because of the underlying metabolic biology.

The practical lesson: you cannot rule PMOS-driving insulin resistance in or out by looking at someone. You have to measure it.

What this means for what you measure

If the engine is metabolic, the workup has to be metabolic. A cycle-focused evaluation that stops at hormones and an ultrasound misses the part that determines your long-term health. A more complete panel looks at:

• Fasting insulin and HOMA-IR, to see insulin resistance directly, rather than fasting glucose alone, which normalizes late
• An oral glucose tolerance test or continuous glucose data, for the fuller picture of how you handle a real glucose load
• Total and free testosterone, plus SHBG and the free androgen index, because the free fraction is what drives symptoms
• A complete lipid panel, ideally with ApoB, since cardiovascular risk is a core, underappreciated feature of the condition
• hs-CRP, as a marker of the inflammation that travels with the metabolic dysfunction
• Body composition, specifically visceral fat, not BMI, which cannot distinguish fat from muscle or tell you where the fat is

This panel does two things. It confirms whether insulin resistance is actually part of your picture, and it sets a baseline for the metabolic and cardiovascular risks that PMOS is now explicitly named to keep in view.

What this means for what you do

If insulin resistance is the engine, the entire logic of treatment is to make your body more insulin sensitive. Everything effective in PMOS works through that lever.

Nutrition that lowers the insulin demand. Approaches that reduce glycemic load help because they ask the pancreas to secrete less insulin in the first place. The broader literature supports Mediterranean-style and lower-carbohydrate patterns, and adequate protein, for improving insulin resistance and the metabolic and reproductive features that follow from it.

Training that pulls glucose out of the blood without insulin. Muscle contraction moves glucose into cells through a pathway that does not depend on insulin, which is why exercise is such a direct insulin-sensitizing tool. Resistance training builds the muscle that acts as a metabolic sink, and high-intensity interval training has specifically been shown to improve insulin resistance in women with the condition. Building and keeping muscle is also what protects you if weight loss enters the picture later.

Sleep and stress, because both move insulin sensitivity. Poor sleep and chronic stress worsen insulin resistance directly. They are not soft add-ons. They are part of the metabolic lever.

Then, pharmacology as an insulin sensitizer. Metformin has long been used off-label in PMOS to improve insulin sensitivity. GLP-1 receptor agonists, covered in depth in our companion articles, act on the same engine from a different angle, improving insulin sensitivity and driving fat loss, with the strongest role in the metabolically high-risk phenotype. The point is that even the drugs are working the same lever as the lifestyle inputs. They are not a different strategy. They are a more powerful version of the same one.

The takeaway

PMOS is a metabolic condition that expresses itself through the ovaries, not an ovarian condition with metabolic footnotes. Insulin resistance and the hyperinsulinemia it triggers sit at the center, driving the androgens, the cycles, the fat storage, and the long-term cardiometabolic risk. That is why the name changed, and it is why the most effective plan starts by measuring insulin resistance directly and then working, through nutrition, training, sleep, and where appropriate medication, to reverse it.

Treat the engine, and the rest of the system follows.

---

This article is educational and is not medical advice. Diagnostic and treatment decisions should be made with a qualified clinician who can evaluate your individual metabolic and hormonal profile.

References

1. Zhao H, et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16:9. DOI 2. Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10:27. DOI 3. Di Lorenzo M, et al. Pathophysiology and nutritional approaches in polycystic ovary syndrome (PCOS): a comprehensive review. Curr Nutr Rep. 2023;12(3):527-544. DOI 4. Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. DOI00717-8) 5. Yang S, et al. The efficacy of various weight loss strategies in alleviating polycystic ovary syndrome. Curr Obes Rep. 2025;14:57. DOI 6. Jensterle M, Janez A. Reframing polycystic ovary syndrome as a complication of obesity: the evolving role of incretin-based therapies. Expert Rev Endocrinol Metab. 2025;20(6):445-448. DOI

Primary literature retrieved via PubMed.